Sonelokimab  (Synonyms: 索洛奇单抗; ALX 0761; M 1095)

Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis^[1][2][3][4].

VH-VH'-VH, trivalent

Humanized

Sonelokimab (2.8 和 10 mg/kg，皮下注射，每周间隔，持续 8 周) 在胶原诱导关节炎的猕猴模型中可以减少 IL-15, IL-6, MMP-3 和 TNF-α 的表达，并显示出潜在的关节炎预防效果^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1414386-05-2

液体

Colorless to light yellow

索洛奇单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  VH-VH'-VH, trivalent

• 
  Loaded Sonelokimab on NTA biosensor, can bind IL-17F Protein, Human (HEK293, His, HY-P70540) with an affinity constant of 2.859E-10 M as determined in BLI assay.
• 
  Loaded Sonelokimab on NTA biosensor, can bind IL-17A (HEK293, His, HY-P70527) with an affinity constant of <1.000E-11 M as determined in BLI assay.

• [1]. Torres T, et al. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25(7):751-4.  [Content Brief]

  [2]. Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289(14):4304-4327.  [Content Brief]

  [3]. Gao W, et al. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. Front Immunol. 2023 May 25;14:1151977.  [Content Brief]

  [4]. Vanheusden K, et al. Pre-clinical proof-of-concept of ALX-0761, a Nanobody® neutralizing both IL-17A and F in a cynomolgus monkey collagen induced arthritis model[C]//ARTHRITIS AND RHEUMATISM. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: Wiley-Blackwell, 2013, 65: S543-S543.